Trafalgar International (GCAN) Change in Accured Expenses (2016 - 2026)
Greater Cannabis Company (GCAN) posted quarterly Change in Accured Expenses of $30000.0 for Q1 2026, little changed year-over-year from $30000.0 in Q1 2025, and up 200.0% quarter-over-quarter from $10000.0 in Q4 2025.
Trafalgar International (GCAN) Change in Accured Expenses (2016 - 2026) Analysis & Trends
Greater Cannabis Company's Change in Accured Expenses history runs 11 years deep, the most recent figure standing at $30000.0 for Q1 2026.
- In Q1 2026, Change in Accured Expenses changed 0.0% year-over-year to $30000.0; the TTM figure through Mar 2026 stood at $90000.0 (up 91.06% YoY), while the FY2025 annual figure was $90000.0, up 295.34% from the prior year.
- Change in Accured Expenses for Q1 2026 stood at $30000.0, up from $10000.0 in the prior quarter.
- The five-year high for Change in Accured Expenses was $56400.0 in Q2 2023, with the low at -$56962.0 in Q4 2023.
- The 5-year median for Change in Accured Expenses is $10000.0 (2023), against an average of $10599.6.
- Peak annual rise in Change in Accured Expenses reached 1445.9% in 2023, while the deepest fall reached 1209.72% in 2023.
- Greater Cannabis Company's Change in Accured Expenses stood at $5133.0 in 2022, then slumped by 1209.72% to -$56962.0 in 2023, then soared by 122.41% to $12765.0 in 2024, then decreased by 21.66% to $10000.0 in 2025, then surged by 200.0% to $30000.0 in 2026.
- Business Quant data shows GCAN's Change in Accured Expenses at $30000.0 in Q1 2026, $10000.0 in Q4 2025, and $30000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.96 Bn | 43.00 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.23 Bn | 39.58 Bn | 2.15 Bn | 82.00 Mn |
| 3 | Zoetis | 31.76 Bn | 30.08 Bn | 1.05 Bn | 142.00 Mn |
| 4 | Takeda Pharmaceutical | 28.68 Bn | 22.88 Bn | 5.10 Bn | -219.00 Mn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | -4.00 Mn |
| 6 | Viatris | 18.69 Bn | 17.81 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn | -8.50 Mn |
| 8 | Elanco Animal Health | 11.78 Bn | 11.25 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - | - |
| 10 | Trafalgar International | 236,233.75 | 236,233.75 | - | 30,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 30,000.00 |
| Mar 31, 2026 | 30,000.00 |
| Dec 31, 2025 | 10,000.00 |
| Dec 31, 2025 | 10,000.00 |
| Sep 30, 2025 | 30,000.00 |
| Sep 30, 2025 | 30,000.00 |
| Jun 30, 2025 | 20,000.00 |
| Jun 30, 2025 | 20,000.00 |
| Mar 31, 2025 | 30,000.00 |
| Mar 31, 2025 | 30,000.00 |
| Dec 31, 2024 | 12,765.00 |
| Dec 31, 2024 | 12,765.00 |
| Sep 30, 2024 | 20,000.00 |
| Sep 30, 2024 | 20,000.00 |
| Jun 30, 2024 | -15,660.00 |
| Jun 30, 2024 | -15,660.00 |
| Mar 31, 2024 | 5,660.00 |
| Mar 31, 2024 | 5,660.00 |
| Dec 31, 2023 | -56,962.00 |
| Dec 31, 2023 | -56,962.00 |